Augmentation von selektiven Serotonin-Wiederaufnahme-Hemmern (SSRI) mit atypischen Antipsychotika in der Depressionsbehandlung

Zusammenfassung

Die Behandlung schwerer Depressionen stellt eine komplizierte Aufgabe in der täglichen psychiatrischen Praxis dar. Augmentationstherapien zur Verbesserung der Wirkung von SSRIs können in bestimmten Fällen hilfreich sein. Seit kurzem besteht die Möglichkeit, zur SSRI-Augmentation atypische Antipsychotika einzusetzen. Diese Option bereichert die bisher bestehenden Strategien in der Depressionstherapie und erste systematische Anwendungsstudien zeigen ermutigende Resultate. In dieser Übersichtsarbeit wird die Möglichkeit einer SSRI-Augmentation insbesondere durch zusätzliche Gabe von Risperidon oder Olanzapin kritisch diskutiert.

Abstract

The treatment of severe depression represents a difficult task in the daily psychiatric practice. In certain cases, augmentation therapies in order to improve the efficacy of SSRIs can be useful. Recently, it has become possible to use atypical antipsychotics for SSRI augmentation. This option adds to the existing strategies in the treatment of depression and primary systematic studies show encouraging results. In this review, the possibility of a SSRI augmentation by additionally administering risperidone or olanzapine is critically discussed.

Literatur

• 1 Landén M, Björling G, Agren H, Fahlén T. A randomized, double-blind, placebo-controlled trial of Buspirone in combination with an SSRI in patients with treatment-refractory depression.  J Clin Psychiatry. 1998;  59 664-668
• 2 Aubry J M, Simon A, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.  J Clin Psychiatry. 2000;  61 649-655
• 3 Fava M. New approaches to the treatment of refractory depression.  J Clin Psychiatry. 2000;  61 26-32
• 4 Nelson J C. Augmentation strategies in depression 2000.  J Clin Psychiatry. 2000;  61 13-19
• 5 Marangell L B. Augmentation of standard depression therapy.  Clin Ther. 2000;  22 25-38
• 6 Li P P, Young L T, Tam Y K, Sibony D, Warsh J J. Effects of chronic lithium and carbamazepine treatment on G-protein subunit expression in rat cerebral cortex.  Biol Psychiatry. 1993;  34 162-170
• 7 Wiborg O, Kruger T, Jakobsen S N. Region-selective effects of long-term lithium and carbamazepine administration on cyclic AMP levels in rat brain.  Pharmacol Toxicol. 1999;  84 88-93
• 8 Post R M, Weiss S R, Chuang D M. Mechanisms of action of anticonvulsants in affective disorders: comparison with lithium.  J Clin Psychopharmacol. 1992;  12 23-35
• 9 Sheline Y I, Wang P W, Gado M H, Csernansky J G, Vannier M W. Hippocampal atrophy in recurrent major depression.  Proc Natl Acad Sci USA. 1996;  93 3908-3913
• 10 Biver F, Goldman S, Delvenne V. et al . Frontal and parietal metabolic disturbances in unipolar depression.  Biol Psychiatry. 1994;  36 381-388
• 11 Thomas P, Vaiva G, Samaille E. et al . Cerebral blood flow in major depression and dysthymia.  J Affect Disord. 1993;  29 235-242
• 12 Hurwitz T A, Clark C, Murphy E, Klonoff H, Martin W R, Pate B D. Regional cerebral glucose metabolism in major depressive disorder.  Can J Psychiatry. 1990;  35 684-688
• 13 Sapolsky R M. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death.  Biol Psychiatry. 2000;  48 755-765
• 14 Smith M A, Makino S, Kvetnansky R, Post R M. Effects of stress on neurotrophic factor expression in the rat brain.  Ann N Y Acad Sci. 1995;  29 234-239
• 15 Duman R S, Heninger G R, Nestler E J. A molecular and cellular theory of depression.  Arch Gen Psychiatry. 1997;  54 597-606
• 16 Duman R S, Malberg J, Thome J. Neural plasticity to stress and antidepressant treatment.  Biol Psychiatry. 1999;  46 1181-1191
• 17 Stewart C A, Reid I C. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity.  Psychopharmacology. 2000;  148 217-223
• 18 Madsen T M, Treschow A, Bengzon J, Bolwig T G, Lindvall O, Tingstrom A. Increased neurogenesis in a model of electroconvulsive therapy.  Biol Psychiatry. 2000;  47 1043-1049
• 19 Thome J, Sakai N, Shin K. et al . cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment.  J Neurosci. 2000;  20 4030-4036
• 20 Suda S, Nibuya M, Ishiguro T, Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment.  J Neurochem. 1998;  71 1554-1563
• 21 Malberg J E, Eisch A J, Nestler E J, Duman R S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.  J Neurosci. 2000;  20 9104-9110
• 22 Harrow M, Yonan C A, Sands J R, Marengo J. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved?.  Schizophr Bull. 1994;  20 327-338
• 23 Jarema M, Murawiec S, Szafranski T, Szaniawska A, Konieczynska Z. Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs.  Psychiatr Pol. 2001;  35 5-19
• 24 Keck P E J, Strakowski S M, McElroy S L. The efficiacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia.  J Clin Psychiatry. 2000;  61 4-9
• 25 Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Auflage. In: Haasen C, (Ed). Bremen: UNI-MED 2000
• 26 Peuskens J, van Baelen B, de Smedt C, Lemmens P. Effects of Risperidone on affective symptoms in patients with schizophrenia.  Int Clin Psychopharmacol. 2000;  15 343-349
• 27 Collaborative working Group on clinical Trial Evaluations . Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders.  J Clin Psychiatry. 1998;  59 41-45
• 28 Healy D. The case for an individual approach to the treatment of depression.  J Clin Psychiatry. 2000;  61 18-23
• 29 O’Connor M, Silver H. Adding Risperidone to selective serotonin reuptake inhibitor improves chronic depression.  J Clin Psychopharmacol. 1998;  18 89-91
• 30 Ostroff R B, Nelson J. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.  J Clin Psychiatry. 1999;  60 256-258
• 31 Lane H-Y, Chiu W-C, Chang W-H. Risperidone monotherapy for mania and depression.  Am J Psychiatry. 1999;  156 1115
• 32 Braus D F, Schmitt A, Czekalla J, Severa L. Therapy-resistant psychotic-depressive disorder. Remission with a selective serotonin reuptake inhibitor in combination with Olanzapin.  Clin Drug Invest. 2000;  20 455-459
• 33 Carlos A ZJ, Narendran R, Tohen M. et al . Clinical predictors of acute response with Olanzapine in psychotic mood disorders.  J Clin Psychiatry. 1998;  59 24-28
• 34 Malhi G S, Checkley S A. Olanzapine in the treatment of psychotic depression.  Br J Psychiat. 1999;  174 460
• 35 Rothschild A J, Bates K S, Boehringer K L, Syed A. Olanzapine response in psychotic depression.  J Clin Psychiatry. 1999;  60 116-118
• 36 Schmitt A, Braus D F. Die effektivere Behandlung einer depressiven Störung mit psychotischen Symptomen durch Kombination mit Olanzapin.  Dtsch Med Wschr. 2000;  125 1526-1529
• 37 Bymaster F P, Rasmussen K, Calligaro D O. et al . In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.  J Clin Psychiatry. 1997;  58 28-36
• 38 Smeraldi E. Amisulpride versus Fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study.  J Affect Dis. 1998;  48 47-56
• 39 Wolfersdorf M, König F RS. Pharmacotherapy of delusional depression: Experience with combinations of antidepressants with the neuroleptics Zotepine and Haloperidol.  Neuropsychobiol. 1994;  29 189-193
• 40 Fulton B, Goa K. Olanzapine - a review of its pharmacological properties and therapeutic efficiancy in the management of schizophrenia and related psychoses.  Drugs. 1997;  53 281-298
• 41 Jacobsen F M. Risperidone in the treatment of affective illness and obsessive-compulsive disorder.  J Clin Psychiatry. 1995;  56 423-429
• 42 McDougle C J, Epperson C N, Pelton G H, Wasylink S, Price L H. A double-blind, placebo-controlled study of Risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.  Arch Gen Psychiatry. 2000;  57 794-801
• 43 Pfanner C, Marazziti D, Dell'¿Osso L. et al . Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study.  Int Clin Psychopharmacol. 2000;  12 297-301
• 44 Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.  Psychiatry Res. 2000;  96 91-98
• 45 Weiss E L, Potenza M N, McDougle C J, Epperson C N. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.  J Clin Psychiatry. 1999;  60 524-527
• 46 Pitchot W, Ansseau M. Addition of Olanzapine for treatment-resistant depression.  Am J Psychiatry. 2001;  158 1737-1738
• 47 König F, von Hippel C, Petersdorff T, Neuhöffer-Weiss M, Wolfersdorf M, Kaschka W P. First experiences in combination therapy using Olanzapine with SSRIs (Citalopram, Paroxetine) in delusional depression.  Neuropsychobiology. 2001;  43 170-173
• 48 Knopf U, Hubrich-Ungureanu P, Thome J. Paroxetin-Augmentation mit Risperidon bei therapieresistenter Depression.  Psychiatrische Praxis. 2001;  im Druck
• 49 Shelton R C, Tollefson G D, Tohen M. et al . A novel augmentation strategy for treating resistant major depression.  Am J Psychiatry. 2001;  158 131-134
• 50 Linnet K, Olesen O V. Monitoring of serum Olanzapine during antipsychotic treatment.  Ugeskr Laeger. 2000;  162 4802-4805
• 51 Heykants J, Huang M, Mannens G. et al . The pharmacokinetics of Risperidone in humans: a summary.  J Clin Psychiatry. 1994;  55 13-17
• 52 Mannens G, Meuldermans W, Huang M, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood.  Psychopharmacology. 1994;  114 566-572
• 53 Barbey J T, Roose S P. SSRI safety in overdose.  J Clin Psychiatry. 1998;  59 42-48
• 54 Capel M M, Colbridge G, Henry J A. Overdose profiles of new antipsychotic agents.  Int J Neuropsychopharmacol. 2000;  3 51-54
• 55 Kopala L C, Day C, Dillman B, Gardner D. A case of Risperidone overdose in early schizophrenia: a review of potential complications.  J Psychiatry Neurosci. 1998;  23 305-308
• 56 Ravin D S, Levenson J W. Fatal cardiac event following initiation of Risperidone therapy.  Ann Pharmacother. 1997;  31 867-870
• 57 Isbister G K, Whyte I M, Smith A J. Olanzapine overdose.  Anaesthesia. 2001;  56 400-401
• 58 Stephens B G, Coleman D E, Baselt R C. Olanzapine-related fatality.  J Forensic Sci. 1998;  43 1252-1253
• 59 Gerber J E, Cawthon B. Overdose and death with Olanzapine: two case reports.  Am J Forensic Med Path. 2000;  21 249-251
• 60 Fogel J, Diaz J E. Olanzapine overdose.  Ann Emerg Med. 1998;  32 275-276
• 61 Lane H-Y, Chang W-H. Risperidone monotherapy for psychotic depression unresponsive to other treatments.  J Clin Psychiatry. 1998;  59 624
• 62 Shelton R C. Mood-stabilizing drugs in depression.  J Clin Psychiatry. 1999;  60 37-40
• 63 Ereshefsky L, Lacombe S. Pharmacological profile of Risperidone.  Can J Psychiatry. 1993;  38 80-88
• 64 Keck P E, McElroy S L, Strakowski S M, Soutullo C A. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.  J Clin Psychiatry. 2000;  61 33-38
• 65 Sechi G, Agnetti V, Masuri R. et al . Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies.  Prog Neuropsychopharmacol Biol Psychiatry. 2000;  24 1043-1051
• 66 Tachikawa H, Suzuki T, Kawanishi Y, Hori M, Hori T, Shiraishi H. Tardive dystonia provoked by concomitantly administered risperidone.  Psychiatry Clin Neurosci. 2000;  54 503-505
• 67 Preskorn S H. Klinische Pharmakologie der selektiven Serotonin-Wiederaufnahmehemmer. In: Caddo, ed. Professional Communications 1997
• 68 Preskorn S H. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.  Clin Pharmacokinet. 1997;  32 1-21
• 69 Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors.  Pharmacol Ther. 2000;  85 11-28
• 70 Ereshefsky L. Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic.  J Clin Psychiatry. 1999;  60 20-30